Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: Troponin I (cTnI-Cardiac panel)

Search for Biomarkers

Analyte:

Troponin I (cTnI-Cardiac panel)

Platform:

Matrix:

Rat Serum

Status:

Experienced Running

Required Sample Volume:

25 µL/well

Sensitivity-LLOQ/ULOQ:

LLOQ: 0.032 ng/mL
ULOQ: 23.5 ng/mL

Biological or Clinical Significance:

Cardiac troponin I, often denoted as cTnI, is presented in cardiac muscle tissue by a single isoform with molecular weight 23876 Da and it consists of 209 amino acid residues. The theoretical pI of cTnI is 9.87. cTnI differs from other troponins due to its N-terminal extension of 26 amino acids. This extension contains two serines, residues 23 and 24, which are phosphorylated by protein kinase A in response to beta-adrenergic stimulation and important in increasing the inotropic response.[1] Phosphorylation of cTnI changes the conformation of the protein and modifies its interaction with other troponins as well as the interaction with anti-TnI antibodies. These changes alter the myofilament response to calcium, and are of interest in targeting heart failure. Multiple reaction monitoring of human cTnI has revealed that there are 14 phosphorylation sites and the pattern of phosphorylation observed these sites is changed in response to disease.[2] cTnI has been shown to be phosphorylated by protein kinase A, protein kinase C, protein kinase G, and p21-activated kinase 3.[3] A significant part of cTnI released into the patient’s blood stream is phosphorylated.[4] For more than 15 years cTnI has been known as a reliable marker of cardiac muscle tissue injury.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies